Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Zhen Wang
Headshot of Zhen Wang
Zhen Wang

Description

Summary

This feasibility study will evaluate how well hyperpolarized 13C pyruvate magnetic resonance imaging (MRI) scan works in predicting tumor aggressiveness in participants with renal tumors. Hyperpolarized 13C pyruvate is a non-radioactive substance with potential usage in the diagnostic imaging of tumors. Hyperpolarized 13C pyruvate MRI may help doctors determine non-invasively whether a kidney tumor is a benign tumor or cancer, and if cancer, how aggressive it is. This may help doctors and participants with renal tumors in the future to make better treatment decisions.

Official Title

Hyperpolarized 13C Pyruvate Metabolic MRI to Predict Renal Tumor Aggressiveness

Details

Keywords

Benign Kidney Neoplasm, Kidney Neoplasm, Renal Cell Cancer, Neoplasms, Renal Cell Carcinoma, Kidney Neoplasms, Aggression, Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Hyperpolarized 13C,15N2-urea

Eligibility

Location

  • UCSF accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Zhen Wang
    Zhen Jane Wang, MD received her undergraduate degree in Electrical Engineering from Brown University, and her medical degree from Northwestern University Medical School. She completed her residency training in Diagnostic Radiology at UCSF in 2007, serving as a Chief Resident from 2006-2007. Dr. Wang subsequently completed a fellowship in Abdominal Imaging at UCSF.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Zhen Wang, MD
ID
NCT04258462
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated